EyePoint announced a Phase III trial failure and a 53% headcount reduction, Enlivex ended preclinical development and laid ...

UK pathology is in the spotlight in the wake of the Pathology Transformation Review 2026. Ravi Chana, head of diagnostics at ...

Loss of exclusivity for Pfizer’s Ibrance could pave the way for a reversal of negative guidance on Roche’s combination drug ...

AstraZeneca says data from the Phase III I CAN trial are intended to support traditional approval for Ultomiris in IgAN.

The European Medicines Agency expects platform trials to play a bigger role in supporting marketing authorization ...

NRx Pharmaceuticals has received a discipline review letter from the US Food and Drug Administration requesting "minor” ...

FDA approval of a new adalimumab manufacturing process and a second drug substance suite in Reykjavik will more than double ...

CAR-T sales are forecast to nearly double by 2032 but sustaining that growth will hinge on earlier-line adoption, next-gen ...

Danaher says it wants to foster more connections between its operating companies across diagnostics and life sciences.

NIH nutrition research and dietary supplement chief Andrew Bremer says providing nutritionals for consumers receiving drug ...

In an Oct. 20 interview, NAD attorney Laura Protzmann said a beauty brand’s exposure for what a chatbot says turns on how ...

Speakers at the DIA Real World Evidence conference urged sponsors and researchers to share clinical trial failures and ...